Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994;91:3497–504.
   PubMed Web of Science ®Google Scholar
• Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000;65:95–106.
   PubMed Web of Science ®Google Scholar
• Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001;276:39359–67.
   PubMed Web of Science ®Google Scholar
• Strauss BE, Haas M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem Biophys Res Commun 1995;217:333–40.
   PubMedGoogle Scholar
• Lo HW, Stephenson L, Cao X, Milas M, Pollock R, Ali-Osman F. Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. Mol Cancer Res 2008;6:843–50.
   PubMed Web of Science ®Google Scholar
• Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990;10:5772–81.
   PubMed Web of Science ®Google Scholar
• Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304–11.
   PubMed Web of Science ®Google Scholar
• Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 1998;292:435–45.
   PubMed Web of Science ®Google Scholar
• Xue C, Haber M, Flemming C, Marshall GM, Lock RB, MacKenzie KL, p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res 2007;67:10351–60.
   PubMedGoogle Scholar
• Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970;30:1174–84.
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152–62.
   PubMed Web of Science ®Google Scholar
• Meijer GA, Schroeijers AB, Flens MJ, Meuwissen SG, van der Valk P, Baak JP, Scheper RJ. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol 1999;52:450–4.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Peters WH, Nagengast FM, Wobbes T. Glutathione S-transferases in normal and cancerous human colon tissue. Carcinogenesis 1989;10:2371–4.
   PubMed Web of Science ®Google Scholar
• Eaton DL, Bammler TK. Concise review of the glutathione S-transferases and their significance to toxicology. Toxicol Sci 1999;49:156–64.
   PubMed Web of Science ®Google Scholar
• Guthenberg C, Akerfeldt K, Mannervik B. Purification of glutathione-S-transferase from human placenta. Acta Chem Scand B 1979;33:595–6.
   PubMedGoogle Scholar
• Jayasurya A, Yap WM, Tan NG, Tan BK, Bay BH. Glutathione S-transferase pi expression in nasopharyngeal cancer. Arch Otolaryngol Head Neck Surg 2002;128:1396–9.
   PubMedGoogle Scholar
• Cairns J, Wright C, Cattan AR, Hall AG, Cantwell BJ, Harris AL, Horne CH. Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas. J Pathol 1992;166:19–25.
   PubMed Web of Science ®Google Scholar
• Hamada S, Kamada M, Furumoto H, Hirao T, Aono T. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 1994;52:313–9.
   PubMed Web of Science ®Google Scholar
• Chen WY, Mao WM, Zhao L, Chen GP, Shu Y, Shen YF, Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance. Zhonghua Zhong Liu Za Zhi 2005;27:738–40.
   PubMedGoogle Scholar
• Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H. Expression of MDR1 and glutathione S transferase-pi genes and chemosensitivities in human gastrointestinal cancer. Cancer 1992;69:941–6.
   PubMed Web of Science ®Google Scholar
• Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459–62.
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin KV. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 1994;6:71–7.
   PubMed Web of Science ®Google Scholar
• Goldsmith ME, Gudas JM, Schneider E, Cowan KH. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 1995;270:1894–8.
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID, AJCC: cancer staging handbook: From the AJCC cancer staging manual. 6th ed. New York: Springer Verlag; 2002. pp 127–9.
   Google Scholar
• Hamilton SR, Aaltonen LA. Tumours of the digestive system, pathology and genetics. World Health Organization Clasification of tumours. IARC press, Lyon; 2000. pp 104–143.
   Google Scholar
• Jurach MT, Meurer L, Moreira LF. Expression of the p53 protein and clinical and pathologic correlation in adenocarcinoma of the rectum. Arq Gastroenterol 2006;43:14–9.
   PubMedGoogle Scholar
• Jakob C, Liersch T, Meyer W, Becker H, Baretton GB, Aust DE. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 2008;14:1060–6.
   PubMed Web of Science ®Google Scholar
• Oka M, Kounoura K, Narasaki F, Sakamoto A, Fukuda M, Matsuo I, P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res 1997;88:738–42.
   PubMedGoogle Scholar
• Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rasmussen AA, Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996;2:1859–65.
   PubMed Web of Science ®Google Scholar
• Blijham GH. Chemotherapy of colorectal cancer. Anticancer Drugs 1991;2:233–45.
   PubMed Web of Science ®Google Scholar
• Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15–6.
   PubMed Web of Science ®Google Scholar
• Ghavam-Nasiri MR, Rezaei E, Ghafarzadegan K, Seilanian-Toosi M, Malekifard H. Expression of p53 in colorectal carcinoma: correlation with clinicopathologic features. Arch Iran Med 2007;10:38–42.
   PubMedGoogle Scholar
• Cohen T, Prus D, Shia J, Abu-Wasel B, Pinto MG, Freund HR, Expression of P53, P27 and KI-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. J Surg Oncol 2008;97:416–22.
   PubMedGoogle Scholar
• Wang JY, Hsieh JS, Lu CY, Yu FJ, Wu JY, Chen FM, The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. Hepatogastroenterology 2007;54:2259–65.
   PubMedGoogle Scholar
• Jeon CH, Lee HI, Shin IH, Park JW. Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients. Int J Colorectal Dis 2008;23:29–35.
   PubMedGoogle Scholar
• Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol 2008;97:51–6.
   PubMedGoogle Scholar
• Buglioni S, D'Agnano I, Vasselli S, Perrone Donnorso R, D'Angelo C, Brenna A, Benevolo M, Cosimelli M, Zupi G, Mottolese M. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. Am J Clin Pathol 2001;116:360–8.
   PubMedGoogle Scholar
• Gallego MG, Aceñero MJ, Ortega S, Delgado AA, Cantero JL. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum. 2000;43:971–5.
   PubMedGoogle Scholar
• Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression.Cell Oncol 2006;28:161–6.
   PubMedGoogle Scholar
• Lim SC, Lee TB, Choi CH, Ryu SY, Kim KJ, Min YD. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in colorectal cancers. Yonsei Med J 2007;48:495–501.
   PubMedGoogle Scholar
• Tabuchi Y, Deguchi H, Imanishi K, Saitoh Y. Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer. Correlation with histopathologic variables. Cancer 1987;59:1283–8.
   PubMed Web of Science ®Google Scholar
• Georgescu CV, Sa˘ftoiu A, Georgescu CC, Ciurea R, Ciurea T. Correlations of proliferation markers, p53 expression and histological findings in colorectal carcinoma. J Gastrointestin Liver Dis 2007;16:133–9.
   PubMedGoogle Scholar
• Juranka PF, Zastawny RL, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989;3:2583–92.
   PubMed Web of Science ®Google Scholar
• van der Valk P, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1990;1:56–64.
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735–8.
   PubMed Web of Science ®Google Scholar
• Meijer GA, Schroeijers AB, Flens MJ, Meuwissen SG, van der Valk P, Baak JP, Scheper RJ. Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J Clin Pathol 1999;52:450–4.
   PubMed Web of Science ®Google Scholar
• Bidgoli SA, Azizi E, Zavarhei MD. Association between p53 expression and Bcl-2, P-glycoprotein, topoisomerase II alpha, thymidylate synthase and thymidine phosphorylase as potential therapeutic targets in colorectal cancer patients. Pak J Biol Sci 2007;10:3350–5.
   PubMedGoogle Scholar
• Sinicrope FA, Hart J, Brasitus TA, Michelassi F, Lee JJ, Safa AR. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 1994;74:2908–17.
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720–6.
   PubMed Web of Science ®Google Scholar
• Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A, Ohsumi K. Effects of MDR1/P-glycoprotein expression on prognosis in advanced colorectal cancer after surgery. Oncol Rep 2001;8:815–9.
   PubMed Web of Science ®Google Scholar
• Sutoh I, Kohno H, Nakashima Y, Hishikawa Y, Tabara H, Tachibana M, Concurrent expressions of metallothionein, glutathione S-transferase-pi, and P-glycoprotein in colorectal cancers. Dis Colon Rectum 2000;43:221–32.
   PubMed Web of Science ®Google Scholar
• Kodate C, Fukushi A, Narita T, Kudo H, Soma Y, Sato K. Human placental form of glutathione S-transferase (GST-pi) as a new immunohistochemical marker for human colonic carcinoma. Jpn J Cancer Res 1986;77:226–9.
   PubMedGoogle Scholar
• Moorghen M, Cairns J, Forrester LM, Hayes JD, Hall A, Cattan AR, Enhanced expression of glutathione S-transferases in colorectal carcinoma compared to non-neoplastic mucosa. Carcinogenesis 1991;12:13–7.
   PubMed Web of Science ®Google Scholar
• Doğru-Abbasoğlu S, Mutlu-Türkoğlu U, Türkoğlu S, Erbil Y, Barbaros U, Uysal M, Aykaç-Toker G. Glutathione S-transferase-pi in malignant tissues and plasma of human colorectal and gastric cancers. J Cancer Res Clin Oncol 2002;128:91–5.
   PubMed Web of Science ®Google Scholar
• Mulder TP, Verspaget HW, Sier CF, Roelofs HM, Ganesh S, Griffioen G, Peters WH. Glutathione S-transferase pi in colorectal tumors is predictive for overall survival. Cancer Res 1995;55:2696–702.
   PubMed Web of Science ®Google Scholar
• de Kant E, Heide I, Thiede C, Herrmann R, Rochlitz CF. MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. J Cancer Res Clin Oncol 1996;122:671–5.
   PubMedGoogle Scholar
• Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 2002;98:323–30.
   PubMedGoogle Scholar
• Zhou CZ, Li Y, Xu J. Correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance. Zhonghua Jie He He Hu Xi Za Zhi 2004;27:678–82.
   PubMedGoogle Scholar
• Sharifi R, Allameh A, Biramijamal F, Mohammadzadeh SH, Rasmi Y, Tavangar SM, Jamali-Zavarei M. Relationship between genetic polymorphism of glutathione S-transferase-p1 and p53 protein accumulation in Iranian esophageal squamous cell carcinoma patients. Indian J Cancer 2008;45:8–12.
   PubMedGoogle Scholar